WHO considerations on Regulatory Convergence of Cell and Gene Therapy Products

whitePaper | December 13, 2022

The global demand for plasmid DNA has increased dramatically in recent years, fueled by a surge in the clinical development of next-generation cell and gene therapy products and more recently by the success of COVID-19 vaccines.

whitePaper | April 20, 2023

In the three decades that have passed since the approval of the first gene therapy in 1990, these revolutionary medicines have changed the lives of patients all over the world1.

whitePaper | May 20, 2022

We are living in a unique time in which the world is changing faster than ever. This largely is due to an influx and infusion of digital technologies that are reinventing and reimagining businesses across nearly every sector, and dramatically shifting societal and economic interactions. While the life science industry has, to some extent, adopted various digital technologies, it has not had a significant digital transformation in how it does business.

whitePaper | February 15, 2023

The discovery of both CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and associated proteins, the Cas nucleases, has revolutionized the field of gene-editing.

whitePaper | August 21, 2022

The “Government Performance and Results Act” and the “GPRA Modernization Act of 2010 require federal agencies to develop strategic plans setting forth long-term goals and objectives. Guidance.

whitePaper | June 8, 2022

Cardinal Health is fortunate to sit at the crossroads of the United States (U.S.) healthcare system, engaging with stakeholders from across the industry including healthcare